Internacional (Marketwired, 12 de Agosto de 2013) ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF) ("ProMetic" or the "Corporation") today announced that it will report its financial results for the second quarter ended June 30, 2013 on Wednesday August 14, 2013 after market trading hours.ProMetic will host a conference call at 11:00am (EDT) on Thursday, August 15, 2013. The telephone numbers to access the conference call are (416) 981-9020 (International) and 1-800-756-3565 (North America Toll-Free). A live audio webcast of the conference call will be available via http://www.gowebcasting.com/4787.
An audio replay of the call will be available for a period of seven days as of Thursday August 15, 2013, at 1:00pm (EDT). The numbers to access the audio replay are (416) 626-4100 (international) and 1 (800) 558-5253 (North America Toll Free) using access code: 21670523.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order tto develop best-in-class therapeutics. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.
President and CEO
ProMetic Life Sciences Inc
Director, Communications & Investor Relations
ProMetic Life Sciences Inc.